Used in pharmaceutical research as a synthetic intermediate for developing central nervous system agents, particularly in the study of anxiolytic and anticonvulsant drugs. Its structure supports binding to benzodiazepine-sensitive sites on GABA receptors or related ion channels involved in neural signaling, making it valuable in the design of novel neuroactive compounds.

Additionally, the compound demonstrates inhibition of the reuptake of certain neurotransmitters, offering potential for development into antidepressants or anxiolytics. Laboratory research has identified anti-inflammatory effects in the nervous system, which may lead to treatments for chronic neurological disorders such as Alzheimer's or Parkinson's disease.

Due to the presence of a sulfoxide group and a fluorinated oxazole structure, this compound exhibits high specificity for biological targets and relatively good stability in the body, making it an attractive option for designing new drugs that require specificity and sustained activity. It is also investigated for potential anti-inflammatory and analgesic properties in preclinical studies.